MK-1602

Allergan · Phase 2 active Small molecule

At a glance

Generic name	MK-1602
Sponsor	Allergan
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006) (PHASE2)
A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MK-1602 CI brief — competitive landscape report
MK-1602 updates RSS · CI watch RSS
Allergan portfolio CI